---
schema_version: "secwatch.filing_event.v1"
accession: "0001378325-25-000039"
form_type: "8-K"
ticker: "CV"
cik: "0001378325"
company_name: "CapsoVision, Inc"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:13:02.124506+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CapsoVision Q3 revenue $3.5M (+19% YoY); FDA submission for pancreatic cancer capsule

## Summary
- Revenue $3.5M (+19% YoY); new accounts up 31%; CapsoCam Plus used by 151k patients.
- Gross profit $1.9M (+16%); gross margin 54% vs 56% in Q3 2024.
- Operating expenses $9.9M (+$2.5M) driven by Canon CMOS development and public company costs.
- Cash $17.8M; July 2025 IPO net proceeds $23.4M.
- Submitted FDA Breakthrough Device Designation for early-stage pancreatic cancer detection; David Garcia appointed SVP Finance.

## SEC filing metadata
- accession: 0001378325-25-000039
- form_type: 8-K
- ticker: CV
- cik: 0001378325
- company_name: CapsoVision, Inc
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1378325/000137832525000039/0001378325-25-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1378325/000137832525000039/cv-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001378325-25-000039
- JSON: https://secwatch.observer/filing/0001378325-25-000039.json
- Plain text: https://secwatch.observer/filing/0001378325-25-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.